In compliance with NIAID/NIH guidelines research at MiraVista Diagnostics utilizing synthetic or recombinant DNA is annually reviewed by the MiraVista Institutional Biosafety Committee (IBC). The IBC is made up of internal and external subject matter experts to ensure that MiraVista is in compliance with research guidelines spelled out in “NIH guidelines for research involving recombinant or synthetic nucleic acid molecules (NIH guidelines)”. The IBC will review current and future research plans in addition to reviewing implementation to ensure MiraVista Diagnostics maintains the highest safety standards. This meeting will occur on March 9th, 2022 at 9:00AM. The meeting is closed to the public but any requests for information can be made to Eric Holbrook.